Search results
Results From The WOW.Com Content Network
Targeted intra-operative radiotherapy, also known as targeted IORT, is a technique of giving radiotherapy to the tissues surrounding a cancer after its surgical removal, a form of intraoperative radiation therapy. The technique was designed in 1998 at the University College London.
Targeted intra-operative radiotherapy is a low-energy IORT technique. Evaluation of the long-term outcomes in patients who were treated with TARGIT-IORT for breast cancer confirmed that it is as effective as whole breast external beam radiotherapy in controlling cancer, and also reduces deaths from other causes [ 16 ] as shown in a large ...
Intraoperative electron radiation therapy is the application of electron radiation directly to the residual tumor or tumor bed during cancer surgery. [1] [2] Electron beams are useful for intraoperative radiation treatment because, depending on the electron energy, the dose falls off rapidly behind the target site, therefore sparing underlying healthy tissue.
When used for IORT, the Xoft System delivers a single, prescribed, targeted dose of isotope-free radiation directly to the tumor cavity during surgery, thereby minimizing radiation to healthy ...
Radiation oncology is the medical specialty ... stomach, or duodenal ulcers [21] [22] This collateral radiation is commonly caused by non-targeted ... IORT was found ...
In early 2000s, Vaidya developed targeted intraoperative radiotherapy for breast cancer. [6] From 2004 to 2008, he was Senior Lecturer at the University of Dundee and the Department of Surgery & Molecular Oncology, Ninewells Hospital , where he led the targeted intraoperative radiotherapy program and related breast cancer research.
Intraoperative radiation therapy or IORT is a special type of radiation therapy that is delivered immediately after surgical removal of cancer. This method has been employed in breast cancer (TARGeted Intra-operative radiation Therapy or TARGIT), brain tumors, and rectal cancers.
Staging breast cancer is the initial step to help physicians determine the most appropriate course of treatment. As of 2016, guidelines incorporated biologic factors, such as tumor grade, cellular proliferation rate, estrogen and progesterone receptor expression, human epidermal growth factor 2 (HER2) expression, and gene expression profiling into the staging system.